Plus Therapeutics announced it will change its name to Cerenome and trade under the new Nasdaq ticker CNSY starting August 3, 2026. The company affirmed its 2026 guidance, focusing on advancing its CNS cancer therapeutic REYOBIQ and expanding its CNSide Diagnostics platform, which has significantly grown payer coverage and physician adoption. Key milestones include progressing clinical trials for REYOBIQ, scaling commercial manufacturing, and expanding CNSide's diagnostic tests and Medicare reimbursement. The rebranding reflects the company's integrated approach combining therapeutics, diagnostics, and AI to improve CNS cancer patient outcomes.
President Trump has sold his shares in Micron Technology and used the proceeds to invest in another large-cap company focused on artificial intelligence. This move highlights a shift in his investment strategy towards the growing AI sector, which is ...
Tesla's stock has shown significant volatility around earnings reports, moving 8% or more after 10 of its last 15 earnings announcements. This pattern highlights the market's strong reaction to Tesla's financial results, making its stock particularly...
Cysic suspended its cross-chain bridge after an unauthorized minting of 10 million CYS tokens on the BNB Smart Chain on October 17, 2026. The incident was limited to the bridge's minting process, with the mainnet and other systems unaffected. About 2...
On October 17, Cysic's cross-chain bridge was attacked, resulting in the unauthorized creation of 10 million CYS tokens on the BNB Chain. Attackers exploited a database flaw to submit fake minting messages. The bridge was immediately paused, and 2.8 ...
XRP was trading at $1.2963, down 1.02% in 24 hours and 7.17% over the past week. Futures open interest stood at $2.76 billion, indicating significant trader activity, with futures volume vastly exceeding spot volume. Market contracts suggest a 50% ch...
